|
Market Closed -
Other stock markets
|
After hours 23:18:47 | |||
| 63.15 USD | -7.51% |
|
63.09 | -0.10% |
| 07-16 | Moderna advances its cancer therapy assessment, but the stock slides |  |
| 07-16 | Arbutus Files More Patent Infringement Suits Against Pfizer, BioNTech -- Update | DJ |
| Market Cap | 27.09B 23.68B 21.9B 20.11B 38.04B 2,610B 38.74B 261B 102B 1,275B 102B 99.51B 4,398B | P/E 2026 * |
-7.88x | P/E 2027 * | -14.4x |
|---|---|---|---|---|---|
| Enterprise Value | 23.69B 20.7B 19.15B 17.58B 33.25B 2,282B 33.87B 228B 89.58B 1,115B 88.93B 87B 3,845B | EV / Sales 2026 * |
11.3x | EV / Sales 2027 * | 9.81x |
| Free-Float |
92.69% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Moderna, Inc.
| 1 day | -0.17% | ||
| 1 week | -14.43% | ||
| Current month | -9.82% | ||
| 1 month | +21.14% | ||
| 3 months | +16.38% | ||
| 6 months | +60.44% | ||
| Current year | +114.14% |
| 1 week | 62.8 |  | 76.72 |
| 1 month | 54.51 | | 85.6 |
| Current year | 29.81 | | 85.6 |
| 1 year | 22.28 | | 85.6 |
| 3 years | 22.28 | | 170.47 |
| 5 years | 22.28 | | 497.49 |
| 10 years | 11.54 | | 497.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 54 | 28/02/2011 |
James Mock
DFI | Director of Finance/CFO | 49 | 05/09/2022 |
Stephen Hoge
PSD | President | 50 | 31/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Noubar Afeyan
CHM | Chairman | 63 | 31/01/2012 |
Stéphane Bancel
BRD | Director/Board Member | 54 | 28/02/2011 |
Francois Nader
BRD | Director/Board Member | 69 | 10/12/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 08/07/26 | Free | Director | 14,766 | 0.0037% | ||
| 05/07/26 | Free | Executive/Senior Manager | 57,022 | 0.0144% | ||
| 02/07/26 | Fiscal year | Chief Financial Officer | 3,607 | 0.0009% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.51% | -14.43% | +99.97% | -47.96% | 27.09B | |
| +2.18% | +2.42% | +23.90% | -5.51% | 67.6B | |
| +0.85% | -4.42% | +39.25% | +199.67% | 51.32B | |
| +0.94% | +39.60% | +39.60% | +39.60% | 42.97B | |
| +0.16% | -1.89% | -51.35% | -53.27% | 40.81B | |
| +5.92% | +4.27% | +63.86% | -25.10% | 29.12B | |
| +1.36% | -0.52% | +70.92% | +88.88% | 22.99B | |
| -2.94% | +9.28% | +9.66% | +190.29% | 21.55B | |
| +2.15% | -1.61% | +58.33% | +129.01% | 16.38B | |
| -2.86% | +2.52% | +70.98% | +340.72% | 16.2B | |
| Average | +0.76% | -0.43% | +42.51% | +85.63% | 33.6B | |
| Weighted average by Cap. | +1.08% | -1.02% | +34.96% | +62.94% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.1B 1.83B 1.69B 1.55B 2.94B 202B 3B 20.19B 7.92B 98.62B 7.87B 7.69B 340B | 2.55B 2.23B 2.06B 1.89B 3.58B 246B 3.65B 24.59B 9.65B 120B 9.58B 9.37B 414B |
| Net income | -3.41B -2.98B -2.76B -2.53B -4.79B -328B -4.88B -32.86B -12.89B -161B -12.8B -12.52B -554B | -1.85B -1.62B -1.49B -1.37B -2.6B -178B -2.64B -17.82B -6.99B -87.05B -6.94B -6.79B -300B |
| Net Debt | -3.41B -2.98B -2.75B -2.53B -4.78B -328B -4.87B -32.82B -12.88B -160B -12.79B -12.51B -553B | -2.05B -1.79B -1.66B -1.52B -2.88B -198B -2.94B -19.79B -7.76B -96.65B -7.71B -7.54B -333B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/07/26 | US$63.15 | -7.51% | 5,572,494 |
| 15/07/26 | US$68.28 | +1.25% | 3,427,825 |
| 14/07/26 | US$67.44 | +0.64% | 5,812,332 |
| 13/07/26 | US$67.01 | -1.85% | 8,521,959 |
| 10/07/26 | US$68.27 | -10.83% | 9,176,930 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MRNA Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
